Octinoxate
drug drugOn this page
Also known as Escalol 557Escalol 557nbEscalol 557tEthylhexyl methoxycinnamateEthylhexyl p-methoxycinnamateEusolex 2292Eusolex uv-pearls omcJeescreen omcNeo heliopan avNSC-26466OcinoxateOctinoxate component of shade uvaguardOctinoxatoOctyl methoxycinnamateOctyl p-methoxycinnamateParsolParsol mcxParsol mcx-saParsol mox
Summary
Octinoxate (CHEMBL3183184) is an approved small molecule (ATC D02BA02); indicated across 3 conditions including sunburn and skin neoplasm.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: D02BA02
- Indications: 3 conditions
- Chemistry: 290.4 Da · C18H26O3
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL3183184 |
| Name | Octinoxate |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | no |
| PubChem CID | 21630 |
| ATC | D02BA02 |
| Molecular formula | C18H26O3 |
| Molecular weight | 290.4 |
| InChIKey | YBGZDTIWKVFICR-UHFFFAOYSA-N |
SMILES: CCCCC(CC)COC(=O)C=CC1=CC=C(C=C1)OC
IUPAC name: 2-ethylhexyl 3-(4-methoxyphenyl)prop-2-enoate
Also known as: Escalol 557, Escalol 557nb, Escalol 557t, Ethylhexyl methoxycinnamate, Ethylhexyl p-methoxycinnamate, Eusolex 2292, Eusolex uv-pearls omc, Jeescreen omc, Neo heliopan av, NSC-26466, Ocinoxate, Octinoxate
Patent coverage: 5,423 distinct patent families (14,006 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).
| Indication | Phase | MONDO | EFO |
|---|---|---|---|
| sunburn | 4 | MONDO:0005326 | EFO:0003958 |
| skin neoplasm | 4 | MONDO:0002531 | MONDO:0002898 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Indicated for: sunburn, skin neoplasm